ArticleKorean journal of ophthalmology : KJO2025
Therapeutic Effect of Topical 0.125% Atropine in South Korean Myopic Children: A Real-World Experience.
Article in Korean journal of ophthalmology : KJO, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Myopia Management Consensus Statement in South Korean Children 2025 by the Korean Myopia Society for the Korean Association for Pediatric Ophthalmology and Strabismus.Korean journal of ophthalmology : KJO · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the effectiveness of 0.125% atropine eye drops in controlling myopia progression by analyzing 1-year follow-up data through a multicenter retrospective study in South Korea.
methodsA retrospective chart review was conducted across five centers, including 121 myopic children (aged 4-11 years) treated with 0.125% atropine between January 2021 and December 2023. An equal number of age-, sex-, axial length (AL)-, and spherical equivalent (SE)-matched untreated individuals (control group) were included. Baseline and follow-up data at 6 and 12 months included visual acuity, autorefraction, AL measurement (IOLMaster 700), and fundus examination. The primary outcome measures were changes in SE and AL compared to controls.
resultsAge, SE, and AL in the treatment group at baseline were 7.5 ± 1.5 years (range, 4 to 11), -3.07 ± 1.65 diopters (D; range, -0.25 to -5.88 D), and 24.39 ± 0.85 mm (range, 22.19 to 26.94 mm), respectively, and these parameters showed no statistical differences compared to the matched controls. SE after 1-year treatment was less myopic in the treatment group (-3.42 ± 1.72 D vs. -3.94 ± 1.92 D, p = 0.019). Similarly, AL was significantly shorter in treatment group compared to the control group (24.65 ± 0.88 mm vs. 24.88 ± 0.80 mm, p = 0.031). The SE change from baseline was -0.33 ± 0.73 D in the treatment group versus -0.91 ± 1.01 D in the control group (p < 0.001). AL increased by 0.25 ± 0.32 mm in the treatment group, significantly less than 0.49 ± 0.24 mm increase in the control group (p < 0.001). Baseline AL and mean keratometry showed no correlation with AL progression (all p > 0.05).
conclusionsThe use of 0.125% atropine eye drops significantly reduced myopia progression, with approximately 50% reduction in AL elongation compared to controls. Given its effectiveness and variable compliance, 0.125% atropine eye drops may serve as a viable alternative to low-dose atropine for myopia control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.